Indianapolis, Indiana
Phase 1 colorectal cancer trials in Indianapolis, IN
12 Phase 1 colorectal cancer studies are recruiting participants at sites in Indianapolis as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Indianapolis at a glance
- 12 studies are recruiting at a site in Indianapolis.
- By phase: Phase 1 (5), Phase 1/2 (7).
- By sponsor: industry (11), university, hospital or other (1).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Indianapolis
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Community Health Network
- Registry record
- NCT06324357 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Indiana University (IU) Health - Multi-D Oncology Clinic
- Registry record
- NCT07488676 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Indiana University (IU) School of Medicine
- Registry record
- NCT07213791 · updated
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Community Health Network
- Registry record
- NCT06663319 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- Community Health Network
- Registry record
- NCT04657068 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #4
- Registry record
- NCT05176483 · updated
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study site
- Indiana University Simon Comprehensive Cancer Center
- Registry record
- NCT06625775 · updated
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Community Health Network
- Registry record
- NCT06128551 · updated
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- InduPro, Inc.
- Study site
- Community Cancer Center North
- Registry record
- NCT07602842 · updated
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Riley Hospital for Children
- Registry record
- NCT04851119 · updated
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Community Health Network, Inc. /ID# 243011
- Registry record
- NCT05005403 · updated
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GV20 Therapeutics
- Study site
- Community Health Network, Inc.
- Registry record
- NCT05669430 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Indianapolis, IN on ClinicalTrials.gov.
Ask about studies near Indianapolis
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections